top of page

About RxCell

Revolutionizing Regenerative Medicine: Hypoimmunogenic iPSC Lines

About RXCELL.png
Screenshot 2023-12-19 at 10.40.57 AM.png

One of our recent triumphs lies in the generation of hypoimmunogenic iPSC lines. Through strategic genome editing genes of both innate and adaptive immune systems we have created hypoimmunogenic (universal) iPSC lines that can evade immune detection/rejection, one of our patented novel technologies. This breakthrough makes it possible to develop a single source of cells that can differentiate into a myriad of therapeutic cells to treat many unrelated patients. Additionally, our patented safe harbor technology facilitates the rapid expression of markers, reporters, factors, and therapeutic products. This allows for the targeted and sustained delivery of biologics to specific locations, advancing the realm of therapeutic possibilities.

Collaboration for Progress: Partnering with Pharmaceutical Companies

RxCell is proud to be at the forefront of therapeutic innovation. In collaboration with both small and large pharmaceutical companies, we are propelling our therapeutic programs forward. Our current focus revolves around leveraging universal iPSC-based allogenic therapies, a groundbreaking initiative with vast implications for the future of medical treatments of many diseases.

Screenshot 2023-12-19 at 10.43.01 AM.png

Beyond Therapeutics: XCell - Empowering Research and Discovery

In addition to our groundbreaking work in therapeutics, RxCell extends its expertise to the academic and drug discovery realms through our XCell brand. Under this banner, we proudly market cells, media, and associated reagents. Our primary emphasis is on producing iPSC-derived neural cells, catering to the diverse needs of drug discovery and research endeavors.

 

At RxCell, we believe in the power of scientific innovation to transform lives. Our journey is fueled by a relentless pursuit of excellence, a commitment to collaboration, and a vision to redefine the landscape of biotechnology. Join us as we continue to push the boundaries of what is possible in the world of induced pluripotent stem cells, making strides towards a healthier, more resilient future.

bottom of page